Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021–August 2022
Eric J. Nilles

, Michael de St. Aubin, Devan Dumas, William Duke, Marie Caroline Etienne, Gabriela Abdalla, Petr Jarolim, Timothy Oasan, Salome Garnier, Naomi Iihoshi, Beatriz Lopez, Lucia de la Cruz, Yosanly Cornelio Puello, Margaret Baldwin, Kathryn W. Roberts, Farah Peña, Kara Durski, Isaac Miguel Sanchez, Sarah M. Gunter, Alexander R. Kneubehl, Kristy O. Murray, Allison Lino, Sarah Strobel, Amado Alejandro Baez, Colleen L. Lau, Adam Kucharski, Emily Zielinski Gutiérrez, Ronald Skewes-Ramm, Marietta Vasquez
1, and Cecilia Then Paulino
1
Author affiliations: Brigham and Women’s Hospital, Boston, Massachusetts, USA (E.J. Nilles, M. de St. Aubin, D. Dumas, M.C. Etienne, G. Abdalla, P. Jarolim, T. Oasan, S. Garnier, N. Iihoshi, M. Baldwin, K.W. Roberts, K. Durski); Harvard Humanitarian Initiative, Cambridge, Massachusetts, USA (E.J. Nilles, M. de St. Aubin, D. Dumas, S. Garnier, M. Baldwin, K.W. Roberts, K. Durski); Harvard Medical School, Boston (E.J. Nilles, P. Jarolim); Pedro Henríquez Ureña National University, Santo Domingo, Dominican Republic (W. Duke); US Centers for Disease Control and Prevention, Central America Regional Office, Guatemala City, Guatemala (B. Lopez, E. Zielinski Gutiérrez); Ministry of Health and Social Assistance, Santo Domingo (L. de la Cruz, Y. Cornelio Puello, F. Peña, I.M. Sanchez, R. Skewes-Ramm, C. Then Paulino); Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas, USA (S.M. Gunter, A.R. Kneubehl, K.O. Murray, A. Lino, S. Strobel); Dominican Republic Office of the Presidency, Santo Domingo (A.A. Baez); University of Queensland, Brisbane, Queensland, Australia (C.L. Lau); London School of Hygiene and Tropical Medicine, London, England, UK (A. Kucharski); Yale School of Medicine, New Haven, Connecticut, USA (M. Vasquez)
Main Article
Table 2
SARS-CoV-2 spike binding antibody serostatus, geometric mean titers, and median titers of participants in study of SARS-CoV-2 spike antibody levels, by study period interval, Dominican Republic, March 2021–August 2022*
Study period interval |
No. patients |
Seropositive, no. (%)† |
GMT (95% CI) |
Median titer, BAU/mL (Q1—Q3) |
Mar–Jun 2021 |
434 |
265 (61.1) |
6.6 (5.1–8.7) |
3.8 (0.4–57.5) |
Jul–Sep 2021 |
397 |
344 (86.6) |
62.8 (45.8–86.0) |
62.5 (6.0–581.8) |
Oct–Dec 2021 |
579 |
543 (93.8) |
559.4 (439.8–711.5) |
781.7 (104.9–4,813.5) |
Jan–Apr 2022 |
463 |
434 (93.7) |
1,180.3 (906.3–1,537.2) |
2,578 (390.8–8,137.5) |
May–Aug 2022 |
427 |
409 (95.8) |
1,332.4 (1,055.3–1,682.3) |
2,876 (775.8–5,483.5) |
Main Article
Page created: January 17, 2023
Page updated: March 20, 2023
Page reviewed: March 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.